Efficacy and Safety of High-Density Lipoprotein/Apolipoprotein A1 Replacement Therapy in Humans and Mice With Atherosclerosis: A Systematic Review and Meta-Analysis
Background: Although elevation of HDL-C levels by pharmaceutical drugs have no benefit of cardiovascular endpoint, the effect of high-density lipoprotein/apolipoprotein A1 (HDL/apoA-1) replacement therapy on atherosclerosis is controversial. The current meta-analysis analyzed the effects of HDL/apoA...
Autors principals: | Ayiguli Abudukeremu, Canxia Huang, Hongwei Li, Runlu Sun, Xiao Liu, Xiaoying Wu, Xiangkun Xie, Jingjing Huang, Jie Zhang, Jinlan Bao, Yuling Zhang |
---|---|
Format: | Article |
Idioma: | English |
Publicat: |
Frontiers Media S.A.
2021-08-01
|
Col·lecció: | Frontiers in Cardiovascular Medicine |
Matèries: | |
Accés en línia: | https://www.frontiersin.org/articles/10.3389/fcvm.2021.700233/full |
Ítems similars
-
Proteomic and functional analysis of HDL subclasses in humans and rats: a proof-of-concept study
per: Canxia Huang, et al.
Publicat: (2023-06-01) -
A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids
per: Mohamad Navab, et al.
Publicat: (2009-08-01) -
Association of human apolipoprotein E with lipoproteins secreted by transfected McA RH7777 cells
per: Catherine A. Reardon, et al.
Publicat: (1998-07-01) -
Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide <span style="font-variant: small-caps">d</span>-[113–122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice
per: Andrea Rivas-Urbina, et al.
Publicat: (2020-05-01) -
Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research
per: Karin Kornmueller, et al.
Publicat: (2019-08-01)